DEL-1: a promising treatment for AMD-associated ER stress in retinal pigment epithelial cells.
J Transl Med
; 22(1): 38, 2024 01 09.
Article
in En
| MEDLINE
| ID: mdl-38195611
ABSTRACT
BACKGROUND:
Age-related macular degeneration (AMD) is an irreversible eye disease that can cause blurred vision. Regular exercise has been suggested as a therapeutic strategy for treating AMD, but how exercise improves AMD is not yet understood. This study investigated the protective effects of developmental endothelial locus-1 (DEL-1), a myokine upregulated during exercise, on endoplasmic reticulum (ER) stress-induced injury in retinal pigment epithelial cells.METHODS:
We evaluated the levels of AMPK phosphorylation, autophagy markers, and ER stress markers in DEL-1-treated human retinal pigment epithelial cells (hRPE) using Western blotting. We also performed cell viability, caspase 3 activity assays, and autophagosome staining.RESULTS:
Our findings showed that treatment with recombinant DEL-1 dose-dependently reduced the impairment of cell viability and caspase 3 activity in tunicamycin-treated hRPE cells. DEL-1 treatment also alleviated tunicamycin-induced ER stress markers and VEGF expression. Moreover, AMPK phosphorylation and autophagy markers were increased in hRPE cells in the presence of DEL-1. However, the effects of DEL-1 on ER stress, VEGF expression, and apoptosis in tunicamycin-treated hRPE cells were reduced by AMPK siRNA or 3-methyladenine (3-MA), an autophagy inhibitor.CONCLUSIONS:
Our study suggests that DEL-1, a myokine, may have potential as a treatment strategy for AMD by attenuating ER stress-induced injury in retinal pigment epithelial cells.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
AMP-Activated Protein Kinases
/
Macular Degeneration
Type of study:
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
J Transl Med
Year:
2024
Type:
Article